Free DNA and Nucleosome Concentrations in Pathological Pregnancies

Our secondary objectives include the following:

• To describe, in 15 healthy, non-pregnant women changes in plasma concentrations of nucleosomes and free DNA over 3 months.
• To describe, in 15 pregnant women (without complications), changes in plasma concentrations of nucleosomes and free DNA over the last 7 months of pregnancy
• To show that plasma concentrations of nucleosomes and free DNA, in patients with complicated pregnancies differ according to the nature of the complication
• To show that a relationship exists between the concentrations of nucleosomes, free DNA, and total granulocyte microparticles (and trophoblast particles for pregnant women)
• To evaluate the relationship between nucleosome concentrations, free DNA concentrations and circulating leukocyte populations
• To evaluate the relationship between nucleosome concentrations, free DNA concentrations and hemostasis markers
• To describe changes in hemostasis markers throughout pregnancy
• To evaluate the relationship between nucleosome concentrations, free DNA concentrations and the angiogenic marker CD146
• To add to the Nîmes University Hospital biological collections.

Inclusion criteria

for all patients:

• The patient must have given her informed and signed consent
• The patient must be insured or beneficiary of a health insurance plan

Inclusion criteria

for patients in group P:

• The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism)

Inclusion criteria

for patients in group T1:

• The patient is available for 3 months of follow-up
• The patient is a non-pregnant healthy volunteer
• No identifiable chronic pathologies
• No history of neoplastic disease
• No history of chronic infectious disease
• No acute disease (such as benign infection), now or within the past two weeks

Inclusion criteria

for patients in group T2:

• The patient is available for 7 months of follow-up
• The patient is pregnant, with no identifiable pregnancy complications
• No identifiable chronic pathologies
• No history of neoplastic disease
• No history of chronic infectious disease
• No acute disease (such as benign infection), now or within the past two weeks

Exclusion criteria

for all patients:

• The patient is participating in another study (with the exception of the following studies: PAPILLO-PMA (2013-A00538-37), ElastoMAP (2013-A01148-37), ElastoDéclenche (2014-A00828-39), LXRs (2009-A00968-49), Bakri (2013-A00914-41), OASIS 2 (2013-A00022-43)).
• The patient is in an exclusion period determined by a previous study
• The patient is under judicial protection, under tutorship or curatorship
• The patient refuses to sign the consent
• It is impossible to correctly inform the patient
• The patient cannot read French
• The patient is receiving hormonal ovarian stimulation in the context of medically assisted procreation
• Impossible to perform venipuncture under good conditions
• New complication or pathology during the study (except for pregnancy complications in group P)

Exclusion criteria

for group P:

• Twin or multiple pregnancy
• The patient is participating in another study (with the exception of those mentioned in the exclusion criteria for all patients and the DG Postpartum study (2013-A00277-38)

Exclusion criteria

for group T1:

• The patient is pregnant
• The patient is breast feeding
• The patient has given birth within the last 3 months
• Known history of chronic disease
• History of treated neoplastic disease
• Acute disease within the past two weeks (includes benign disease)

Exclusion criteria

for group T2:

• Pregnancy with complications
• Known history of chronic disease
• History of treated neoplastic disease
• Acute disease within the past two weeks (includes benign disease)
• Twin or multiple pregnancy